Annovis Bio to Present Comprehensive Buntanetap Data at Parkinson Study Group Meeting

Annovis Bio Inc. (NYSE: ANVS) announced it will present new findings on its drug candidate buntanetap at the 2025 Annual Meeting of the Parkinson Study Group in San Diego. The presentation will expand on recent Phase 3 Parkinson's biomarker results demonstrating that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap treatment. This reversal occurs alongside reductions in tau biomarkers, which are directly linked to disease progression in neurodegenerative conditions.

The company will also debut a cross-study comparison of all completed trials, providing the most comprehensive analysis to date of cognitive outcomes across different indications. This comparison underscores that patients with amyloid pathology achieve the greatest cognitive benefit from buntanetap treatment. These findings support the company's strategic path forward in developing therapies for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.

The presentation at the Parkinson Study Group meeting represents a significant step in understanding buntanetap's mechanism and potential clinical applications. By demonstrating reversal of cognitive decline specifically in patients with amyloid co-pathology, the data suggests a targeted approach to treating neurodegenerative diseases based on underlying pathology. The reduction of tau biomarkers further indicates buntanetap's potential to address fundamental disease processes beyond symptom management.

For additional information about Annovis Bio, visit https://www.annovisbio.com. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. For more information about InvestorWire, please visit https://www.InvestorWire.com.